Ganar perdiendo: la ruta de emprender | Ángela Pérez | TEDxValencia

Quick Overview

The speaker recounts her entrepreneurial journey in genomics, emphasizing that initial success, despite financial constraints and external skepticism, came from making difficult decisions like prioritizing the continuation of her PhD over the company's immediate financial needs, ultimately leading to the company's survival and growth.

Key Points: The speaker's family had limited resources, but her mother (a housewife) and father (a factory worker) instilled a strong conviction and a single goal: supporting the speaker's university education. The speaker chose Biology and, in the 1990s, entered genomics research at the University of Valencia, noting that sequencing technology was nascent and underfunded compared to the US. A key turning point was when the project secured $3 billion in US funding, but the Spanish team, despite producing world-class research, struggled with European funding and lacked the necessary capital. The speaker and her partner decided to found a biotech company based on their technology, deliberately avoiding selling to large corporations early on. They rejected an offer from a US company that wanted to acquire their technology and only provide 9% ownership, opting instead to secure loans and operate independently. After years of hard work, they successfully navigated regulatory hurdles and secured funding, allowing them to grow the company and eventually reverse the initial decision to sell. The speaker's key takeaway is that entrepreneurs must be prepared to 'win by losing'—making sacrifices (like delaying her PhD or turning down immediate cash) for long-term vision and control.

Context: This TEDx talk by Ángela Pérez frames her entrepreneurial narrative within the context of scientific discovery and business survival, specifically focusing on the challenges of launching a genomics company in Spain during the 1990s when the field was less funded than in the US. The story pivots on the tension between financial necessity, external control, and maintaining the vision for their proprietary DNA sequencing technology.